Has Amerise BioScie declared dividend?

No Dividend History Available

Is Amerise BioScie overvalued or undervalued?

As of May 20, 2025, Amerise Biosciences Ltd. is considered very expensive and overvalued, with a PE ratio of 5.75, an EV to EBITDA ratio of 5.73, and a significant disparity in earnings growth expectations, despite a 46.67% return over the past year compared to the Sensex's 7.55%, but a long-term decline of -85.26% over 10 years versus the Sensex's 211.47%.

As of 20 May 2025, the valuation grade for Amerise Biosciences Ltd. has moved from risky to very expensive. The company is currently considered overvalued. Key ratios include a PE ratio of 5.75, an EV to EBITDA ratio of 5.73, and a PEG ratio of 0.05, which indicates a significant disparity between its earnings growth expectations and its current price.<BR><BR>In comparison to its peers, Amerise Biosciences Ltd. has a similar PE ratio to its closest competitor, but both are categorized as very expensive. Notably, the company's return over the past year stands at 46.67%, significantly outperforming the Sensex's return of 7.55% in the same period. However, the long-term performance shows a decline, with a 10-year return of -85.26% compared to the Sensex's 211.47%, reinforcing the perception of overvaluation in the current market context.

What is the technical trend for Amerise BioScie?

As of May 12, 2025, Amerise BioScie shows a mildly bearish trend with mixed signals from various indicators, suggesting weak current momentum but some potential for recovery in the longer term.

As of 12 May 2025, the technical trend for Amerise BioScie has changed from bearish to mildly bearish. The weekly MACD remains bearish, while the monthly MACD is mildly bullish, indicating mixed signals across time frames. The daily moving averages are mildly bearish, and the weekly Bollinger Bands also reflect a mildly bearish stance. The KST shows bearish momentum on the weekly chart but is bullish on the monthly chart. Overall, the indicators suggest a mildly bearish sentiment with some potential for recovery in the longer term, but current momentum is weak.

Who are the peers of the Amerise BioScie?

Amerise BioScie's peers include Ashish Polyplast, Kkalpana Plastic, Bloom Dekor, Polymac Thermof., Integ. Thermopl., Innocorp, Krishna Fil. Ind, and Arcee Industries. Amerise BioScie has Below Average management risk, Excellent growth, and a 1-year return of 9.86%, while Innocorp leads with a 10.31% return.

Peers: The peers of Amerise BioScie are Ashish Polyplast, Kkalpana Plastic, Bloom Dekor, Polymac Thermof., Integ. Thermopl., Innocorp, Krishna Fil. Ind, and Arcee Industries.<BR><BR>Quality Snapshot: Below Average management risk is observed at Ashish Polyplast, Polymac Thermof., Integ. Thermopl., Arcee Industries, and the rest. Good management risk is found at Innocorp, while Amerise BioScie has Below Average management risk. Growth is Excellent at Amerise BioScie, while Below Average growth is seen at Ashish Polyplast, Polymac Thermof., Integ. Thermopl., and Arcee Industries, and the rest. Innocorp shows Good growth, while Kkalpana Plastic, Bloom Dekor, and Krishna Fil. Ind do not qualify for growth assessment. Capital Structure is Excellent at Amerise BioScie, Good at Ashish Polyplast, and Below Average at Polymac Thermof., Integ. Thermopl., Arcee Industries, and the rest, with Innocorp having Below Average capital structure.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Innocorp at 10.31%, while the lowest is Ashish Polyplast at -56.03%. Amerise BioScie has a 1-year return of 9.86%, which is higher than Ashish Polyplast but lower than Innocorp. Additionally, the peers with negative six-month returns include Ashish Polyplast, Polymac Thermof., Integ. Thermopl., and Arcee Industries.

Who are in the management team of Amerise BioScie?

As of March 2022, the management team of Amerise BioScie includes Manisha Maneklal Patel (Independent Director), Dineshkumar Tribhovanbhai Rathod (Whole-time Director), Minal Lakhlani (Company Secretary & Compliance Officer), and Niraj Vaghela (Independent Director).

As of March 2022, the management team of Amerise BioScie includes the following individuals:<BR><BR>1. Manisha Maneklal Patel - Independent Director<BR>2. Dineshkumar Tribhovanbhai Rathod - Whole-time Director<BR>3. Minal Lakhlani - Company Secretary & Compliance Officer<BR>4. Niraj Vaghela - Independent Director<BR><BR>These individuals play key roles in the governance and management of the company.

What does Amerise BioScie do?

Amerise Biosciences Ltd is a manufacturer of construction and agricultural equipment, incorporated in 1984 and recently renamed in 2021. As of March 2025, it reported a net profit of 1 Cr and has a market cap of INR 5 Cr.

Overview:<BR>Amerise Biosciences Ltd is a specialized manufacturer of high-quality construction and agricultural equipment, operating within the Micro Cap category in the Plastic Products - Industrial industry.<BR><BR>History:<BR>The company was incorporated in 1984 and has undergone several name changes, from Amstar Laminates Limited to Amardeep Industries Limited, and finally to Amerise Biosciences Limited in August 2021. The most recent quarterly results reported net profit for March 2025.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: N/A<BR>Most recent Net Profit: 1 Cr (Quarterly Results - Mar 2025)<BR>Market-cap value: INR 5 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: 5.00<BR>Industry P/E: 23<BR>Dividend Yield: 0.00%<BR>Debt-Equity: 0.00<BR>Return on Equity: 0.19%<BR>Price-to-Book: 0.97<BR><BR>Contact Details:<BR>Address: PO5-02D 5th Floor Tower A WTC, Gift City Gandhinagar Gujarat : 382355<BR>Email: amradeepindustries@gmail.com<BR>Website: http://www.amradeepindustries.quest

Who are the top shareholders of the Amerise BioScie?

The top shareholders of Amerise BioScie are mainly individual investors, holding 72.09% of the shares, with Amrapali Industries Limited as the largest public shareholder at 4.4%. There are no institutional investors or pledged promoter holdings.

The top shareholders of Amerise BioScie are primarily individual investors, who hold a significant 72.09% of the shares. Among the public shareholders, Amrapali Industries Limited stands out with a holding of 4.4%. There are no institutional shareholders, mutual funds, or foreign institutional investors involved in the company's shareholding structure. Additionally, there are no pledged promoter holdings or a specific promoter with the highest stake.

How big is Amerise BioScie?

As of 24th July, Amerise Biosciences Ltd has a market capitalization of 5.00 Cr, with reported Net Sales of 0.00 Cr and a Net Profit of 0.01 Cr in the latest four quarters. Shareholder's Funds are 5.37 Cr and Total Assets are 5.39 Cr as of March 2024.

As of 24th July, Amerise Biosciences Ltd has a market capitalization of 5.00 Cr, which classifies it as a Micro Cap company.<BR><BR>In the latest four quarters, the company reported Net Sales of 0.00 Cr and a Net Profit of 0.01 Cr.<BR><BR>The latest annual period for the balance sheet is March 2024, with Shareholder's Funds amounting to 5.37 Cr and Total Assets of 5.39 Cr.

When is the next results date for Amerise BioScie?

Amerise BioScie is scheduled to announce its results on November 5, 2025.

Amerise BioScie is scheduled to declare its results on November 5, 2025.

How has been the historical performance of Amerise BioScie?

Amerise BioScie has shown minimal revenue generation, with net sales at zero from March 2020 to March 2025, and a significant decline in operating income from 9.01 crore in March 2022 to 0.19 crore in March 2025. While expenditures decreased and cash flow turned positive in March 2025, overall profitability remains weak, with profit after tax at only 0.01 crore.

Answer:<BR>The historical performance of Amerise BioScie shows a trend of minimal activity and fluctuating financial metrics over the years, with net sales consistently at zero from March 2020 to March 2025. Other operating income peaked at 9.01 crore in March 2022 but has since declined to 0.19 crore in March 2025. Total operating income followed a similar pattern, dropping from 9.01 crore in March 2022 to 0.19 crore in March 2025. The company reported total expenditure excluding depreciation of 0.18 crore in March 2025, which is significantly lower than the 9.03 crore recorded in March 2022. Operating profit (PBDIT) showed a recovery to 0.01 crore in March 2025 from a loss of 0.34 crore in March 2021, but overall profitability remains weak, with profit after tax at 0.01 crore in March 2025 compared to a profit of 0.55 crore in March 2022. The balance sheet reflects total liabilities of 8.46 crore in March 2025, up from 5.39 crore in March 2024, while total assets also increased to 8.46 crore in March 2025 from 5.39 crore in March 2024. Cash flow from operating activities was positive at 3.00 crore in March 2025, contrasting with previous years where cash flow was non-existent.<BR><BR>Breakdown:<BR>Amerise BioScie's financial history indicates a lack of revenue generation, with net sales remaining at zero from March 2020 to March 2025. The company experienced a significant drop in other operating income from a high of 9.01 crore in March 2022 to just 0.19 crore in March 2025, leading to a total operating income that also fell sharply. Expenditures were notably high in March 2022 but have since decreased, resulting in a slight operating profit in March 2025. Despite this, the company has struggled to maintain profitability, with profit after tax only reaching 0.01 crore in March 2025. The balance sheet shows a rise in total liabilities and assets, indicating some growth, while cash flow from operating activities turned positive in March 2025, marking a potential turning point for the company.

Which are the latest news on Amerise BioScie?

Why is Amerise BioScie falling/rising?

As of 04-Dec, Amerise Biosciences Ltd's stock price is at 0.60, reflecting a significant decline of 50.41% year-to-date and underperformance compared to the Sensex. The stock is trading below all moving averages, indicating a bearish trend.

As of 04-Dec, Amerise Biosciences Ltd's stock price is falling, currently at 0.60, which reflects a decrease of 0.01 or 1.64%. The stock has underperformed significantly compared to the benchmark Sensex, with a 1-week decline of 3.23% against the Sensex's 0.53% drop, and a 1-month decline of 6.25% while the Sensex gained 2.16%. Year-to-date, the stock has plummeted by 50.41%, contrasting sharply with the Sensex's increase of 9.12%. Over the past year, the stock has also decreased by 45.95%, while the Sensex has risen by 5.32%. <BR><BR>Additionally, the stock is trading below all its moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, indicating a bearish trend. Despite a rise in delivery volume by 6.5% on December 3rd, the overall performance today shows that it has underperformed its sector by 1.76%. This combination of factors contributes to the ongoing decline in the stock's price.